Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock

Blackstone Life Sciences announces a $455 million collaboration with Boston Scientific to co-fund the development of VITALYST, a next-generation miniature heart pump. The partnership aims to advance a new medical device for treating life-threatening cardiogenic shock, supporting innovation in cardiovascular care.

Cambridge, MA – November 2, 2026 – Blackstone Life Sciences (“BXLS”) today announced a $455 million collaboration with Boston Scientific Corporation (NYSE: BSX) to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The VITALYST system is a next-generation, miniature heart pump intended to increase cardiac output and improve blood flow from the heart to the brain and other vital organs. It is designed to treat acute myocardial infarction cardiogenic shock (AMI-CS), a life-threatening medical emergency where the heart cannot pump enough blood to supply the brain and other organs with oxygen. This is the first time that Boston Scientific and BXLS will co-fund the development of a Boston Scientific product.

Cardiogenic shock, caused by heart attack or other heart issues, is associated with significant mortality despite advances in treatment. The VITALYST system is being developed to address the core unmet needs of these critically ill patients, with the goal of improving efficacy, safety, and ease of use for the physicians treating them.

“Boston Scientific has built a leading cardiovascular franchise, with deep expertise in developing and commercializing transformative technologies for patients and physicians,” said Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences. “We believe the VITALYST system has the potential to improve on the efficacy and safety of currently available mechanical circulatory support technologies, and this collaboration reflects our ability to help leaders in innovation bring important new medical devices to patients.”

About Blackstone Life Sciences
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $18 billion in assets under management.

Contact
David Vitek
(212) 583-5291
David.Vitek@Blackstone.com

LikeDiscussion

Discussion

You are commenting on Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock

You must be logged in to add a comment

There are no comments

Be the first to add to the discussion

Fund manager

Blackstone Group

New York, United States

Blackstone is the world’s largest alternative asset manager. We seek to deliver compelling returns for institutional and individual investors by strengthening the companies in which we invest. Our more than $1 trillion in assets under management include global investment strategies focused on real estate, private equity, infrastructure, life sciences, growth equity, credit, real assets, secondaries and hedge funds.

buyoutprivate equityinfrastructurereal estategrowthprivate debt

Related news

Blackstone Announces Final Close of Record $6.3 Billion Life Sciences Fund – the Largest Private Fund Dedicated to Life Sciences

Blackstone announced the final close of its Life Sciences VI fund at $6.3 billion, making it the largest life sciences private fund ever and significantly larger than its predecessor, reflecting strong investor demand and an oversubscribed raise.

Blackstone Group

Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront

Novartis completes its acquisition of Anthos Therapeutics in a deal valued at up to $3.1 billion, confirming Blackstone Life Sciences’ strategy of building companies around innovative treatments to address unmet medical needs.

Blackstone Group

Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion

Novartis announces an agreement to acquire Anthos Therapeutics for up to $3.1 billion, highlighting the promise of Anthos’ lead asset, abelacimab, a novel Factor XI inhibitor developed to prevent strokes and blood clots.

Blackstone Group

Blackstone Life Sciences Announces a Co-funding Agreement for Acute Myeloid Leukemia

Blackstone Life Sciences and Johnson & Johnson have entered their first co-funding agreement to support clinical trials of bleximenib, an investigational oral treatment for acute myeloid leukemia (AML).

Blackstone Group

Ajax Health and KKR Form New Platform to Develop System for Treating Heart Failure

Ajax Health, KKR, and Boston Scientific Launch FlowMod to Advance Heart Failure Treatment FlowMod, a newly formed entity backed by Ajax Health, KKR, and Boston Scientific, aims to accelerate the development, clinical validation, and regulatory approval of an innovative system for treating heart failure, a condition affecting 64 million people worldwide.

KKR

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency

Blackstone Life Sciences has invested $250 million in Anagram Therapeutics to support the development and commercialization of ANG003, a next-generation treatment for exocrine pancreatic insufficiency.

Blackstone Group

Blackstone Announces Agreement to Acquire Enverus

Blackstone has agreed to acquire Enverus, a leading energy-focused SaaS and data analytics platform, from Hellman & Friedman and Genstar Capital.

Blackstone Group

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

Axsome Therapeutics has entered into a new $570 million credit facility with Blackstone Life Sciences and Blackstone Credit & Insurance, consisting of a $500 million term loan and a $70 million revolving credit facility.

Blackstone Group

Blackstone Launches BXPM – Blackstone Private Markets Fund

Blackstone launches BXPM, a perpetual multi-strategy fund giving eligible non-U.S. investors simplified access to private equity, infrastructure, real estate and private credit. The launch expands Blackstone’s private wealth offering by combining its institutional private-markets capabilities into a single portfolio allocation.

Blackstone Group

Blackstone Credit & Insurance Leads $1.3 Billion Financing to Support Combination of Paratek Pharmaceuticals and Radius Health

Blackstone Credit & Insurance is leading a $1.3 billion financing to support the merger of Paratek Pharmaceuticals and Radius Health, creating a larger specialty pharmaceutical platform with diversified medicines and strong growth potential.

Blackstone Group